Abstract:Recent research has indicated that the abnormal expression of the deubiquitinase USP7 induces tumorigenesis via multiple cell pathways, and in particular, the p53-MDM2-USP7 pathway is well understood. USP7 is emerging as a promising target for cancer therapy. However, there are limited reports on USP7 inhibitors. Here we report design, synthesis and biological evaluation of novel quinazolin-4(3H)-one derivatives as potent USP7 inhibitors. Our results indicated that the compounds C9 and C19 exhibited the greatest potency against the USP7 catalytic domain, with IC50 values of 4.86 μM and 1.537 μM, respectively. Ub-AMC assays further confirmed IC50 values of 5.048 μM for C9 and 0.595 μM for C19. MTT assays indicated that gastric cancer MGC-803 cells were more sensitive to these compounds than BGC-823 cells. Flow cytometry analysis revealed that C9 restricted cancer cell growth at the G0/G1 and S phases and inhibited the proliferation and clone formation of MGC-803 cells. Further biochemical experiments indicated that C9 decreased the MDM2 protein level and increased the levels of the tumour suppressors p53 and p21 in a dose-dependent manner. Docking studies predicted that solvent exposure of the side chains of C9 and C19 would uniquely form hydrogen bonds with Met407 of USP7. Additionally, C9 exhibited a remarkable anticancer effect in a zebrafish gastric cancer MGC-803 cell model. Our results demonstrated that quinazolin-4(3H)-one derivatives were suitable as leads for the development of novel USP7 inhibitors and especially for anti-gastric cancer drugs.

Synthesis and Biological Evaluation of Thiazole Derivatives As Novel USP7 Inhibitors.

Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors

Design, Synthesis and Biological Evaluation of 2-Aminopyridine Derivatives As USP7 Inhibitors.

USP7: Target Validation and Drug Discovery for Cancer Therapy

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Design, Synthesis, and Biological Evaluation of Pyrido[2,3-d]pyrimidin-7(8H)-one Derivatives As Potent USP1 Inhibitors

Virtual screening of natural products targeting ubiquitin-specific protease 7

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

N-benzylpiperidinol Derivatives As Novel USP7 Inhibitors: Structure-activity Relationships and X-ray Crystallographic Studies

Gardenin B, a Natural Inhibitor for USP7: in Vitro Evaluation and in Silico Identification

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

Advances in research on a novel anticancer target USP7 and its inhibitors

Virtual Screening Inhibitors of Ubiquitin‐specific Protease 7 combining Pharmacophore Modeling and Molecular Docking

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy

Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity

Design and Synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides As Novel Hsp90 Inhibitors.

Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy

Characterization of Naturally Occurring Pentacyclic Triterpenes As Novel Inhibitors of Deubiquitinating Protease USP7 with Anticancer Activity in Vitro